Literature DB >> 14522497

Is there a referral bias against catheterization of patients with reduced left ventricular ejection fraction? Influence of ejection fraction and inducible ischemia on post-single-photon emission computed tomography management of patients without a history of coronary artery disease.

Rory Hachamovitch1, Sean W Hayes, John D Friedman, Ishac Cohen, Xingping Kang, Guido Germano, Daniel S Berman.   

Abstract

OBJECTIVES: The objective of this work was to define the relationship between left ventricular perfusion/ function measures and referral rates to catheterization and revascularization early after stress gated myocardial perfusion single-photon emission computed tomography (MPS).
BACKGROUND: Although revascularization yields the greatest survival benefit in patients with low ejection fraction (EF) and extensive coronary artery disease, referral patterns to catheterization and revascularization after noninvasive testing are not well defined.
METHODS: We identified 3,369 patients without previous myocardial infarction or revascularization who underwent exercise or adenosine stress MPS and who were followed-up (97% complete) for occurrence of early (<60 days) post-single-photon emission computed tomography (SPECT) revascularization. Multivariable logistic regression modeling was used to determine the association of various patient characteristics and test results with performance of catheterization and revascularization as separate end points.
RESULTS: In the first 60 days after stress MPS, 445 catheterizations (13.2%) and 254 revascularizations (7.5%) occurred, including 140 coronary artery bypass graft surgeries (4.1%) and 114 percutaneous coronary interventions (3.4%). Both post-stress gated EF and percent of the myocardium ischemic by stress MPS were independent predictors of revascularization. Logistic regression revealed that the likelihood of catheterization increased with both increasing ischemia and decreasing EF (c-index = 0.94, chi-square = 590). Predicted referral rates to catheterization increased with decreasing EF except in patients with severe ischemia (>15% of myocardium), where rates decreased with decreasing EF. Similar modeling of revascularization (c-index = 0.94, chi-square = 329) revealed that the likelihood of revascularization increased with increasing ischemia but, in general, decreased with decreasing EF.
CONCLUSIONS: Although post-SPECT referral to both catheterization and revascularization is driven by ischemia, EF has the opposite effect on these two outcomes. Further studies evaluating the appropriateness of these referral patterns are warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522497     DOI: 10.1016/s0735-1097(03)00991-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

Review 1.  Gated SPECT in assessment of regional and global left ventricular function: major tool of modern nuclear imaging.

Authors:  Aiden Abidov; Guido Germano; Rory Hachamovitch; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

2.  What should we expect in a prognosis study in 2012?

Authors:  Rory Hachamovitch
Journal:  J Nucl Cardiol       Date:  2012-10       Impact factor: 5.952

3.  Prognostic value of poststress left ventricular volume and ejection fraction by gated myocardial perfusion SPECT in women and men: gender-related differences in normal limits and outcomes.

Authors:  Tali Sharir; Xingping Kang; Guido Germano; Jeroen J Bax; Leslee J Shaw; Heidi Gransar; Ishac Cohen; Sean W Hayes; John D Friedman; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2006-07       Impact factor: 5.952

4.  Has anyone been listening? Post-SPECT MPI referral rates to catheterization.

Authors:  Elizabeth Hill; Rory Hachamovitch
Journal:  J Nucl Cardiol       Date:  2016-06-29       Impact factor: 5.952

5.  How and when to decide on revascularization in stable ischemic heart disease.

Authors:  Alicia Mecklai; Sripal Bangalore; Judith Hochman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

Review 6.  Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging.

Authors:  Leslee J Shaw; Daniel S Berman; Michael H Picard; Matthias G Friedrich; Raymond Y Kwong; Gregg W Stone; Roxy Senior; James K Min; Rory Hachamovitch; Marielle Scherrer-Crosbie; Jennifer H Mieres; Thomas H Marwick; Lawrence M Phillips; Farooq A Chaudhry; Patricia A Pellikka; Piotr Slomka; Andrew E Arai; Ami E Iskandrian; Timothy M Bateman; Gary V Heller; Todd D Miller; Eike Nagel; Abhinav Goyal; Salvador Borges-Neto; William E Boden; Harmony R Reynolds; Judith S Hochman; David J Maron; Pamela S Douglas
Journal:  JACC Cardiovasc Imaging       Date:  2014-06

7.  Prognostic value of myocardium perfusion imaging with a new reconstruction algorithm.

Authors:  Ronaldo Lima; Lima Ronaldo; Andrea De Lorenzo; De Lorenzo Andrea; Gabriel Camargo; Camargo Gabriel; Gabriel Oliveira; Oliveira Gabriel; Thiago Reis; Reis Thiago; Thais Peclat; Peclat Thais; Tamara Rothstein; Rothstein Tamara; Ilan Gottlieb; Gottlieb Ilan
Journal:  J Nucl Cardiol       Date:  2013-11-27       Impact factor: 5.952

8.  Hemodynamic variables during stress testing can predict referral to early catheterization but failed to show a prognostic impact on emerging cardiac events in patients aged 70 years and older undergoing exercise (99m)Tc-sestamibi myocardial perfusion scintigraphy.

Authors:  Jan Bucerius; Alexius Y Joe; Ellen Herder; Holger Brockmann; Kim Biermann; Holger Palmedo; Klaus Tiemann; Hans-Jürgen Biersack
Journal:  Int J Cardiovasc Imaging       Date:  2009-04-21       Impact factor: 2.357

9.  Outcome of revascularisation in stable coronary artery disease without ischaemia: a Danish registry-based follow-up study.

Authors:  Jane Angel Simonsen; Hans Mickley; Allan Johansen; Søren Hess; Anders Thomassen; Oke Gerke; Lisette O Jensen; Jesper Hallas; Werner Vach; Poul F Hoilund-Carlsen
Journal:  BMJ Open       Date:  2017-08-11       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.